Precision Medicine in Severe Asthma

Severe asthma affects only 3-6% of the overall population of asthmatics but accounts for nearly half of the annual expenditures among asthma patients. Advances in the understanding of the pathophysiology of severe asthma have led to the identification of specific asthma endotypes and phenotypes that may be used to better tailor therapy in the future.

Share

Program Content

Activities

  • The Importance of Phenotypes and Endotypes in Patient Evaluation
    Precision Medicine in Severe Asthma: The Importance of Phenotypes and Endotypes in Patient Evaluation
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2019

    Expires: September 13, 2020

  • How Phenotypes and Endotypes Guide Treatment Decisions
    Precision Medicine in Severe Asthma: How Phenotypes and Endotypes Guide Treatment Decisions
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2019

    Expires: September 13, 2020

Faculty

cover img faculity

Emily DiMango, MD

Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Columbia University Medical Center
New York, New York

cover img faculity

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director,
NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Novartis Pharmaceuticals Corporation

Sanofi Genzyme and Regeneron Pharmaceuticals